Because of their behaviour against alleged patent infringements by Indian pharmaceutical manufacturers, according to the German Financial Times (FTD) the EU gets pressurised.
EU blocks generics for Third World countries
Home/Policies & Legislation
|
Posted 23/11/2009
0
Post your comment

Several customs authorities, among them authorities in Germany and The Netherlands, seized several generics deliveries during the past months that had been produced in India and were meant for other developing countries. The suspicion existed that these medicines would hurt EU patients, was given as a reason. However, according to legal experts, the EU provisions in Third World countries producing ‘me too’ products infringe the regulations of the World Trade Organization (WTO).
India’s WTO representative, Mr Rati Bengar, also said that the authorities would not have been allowed to hinder the transit, because the generics were not intended for the EU market, but for other countries in South America and the like. India now threatens the EU with a suit at the WTO if she does not suppress this practice.
At the EU Committee they rate the legal position of the incident differently. A spokesman for Trade Commissioner Catherine Ashton said that they knew cases in which generics in transit had been seized temporarily. “According to EU Law, this is allowed—also in accordance with WTO rules—if a suspicion exists that the goods violate intellectual property rights or are even counterfeit or dangerous,” said the spokesman.
India and the EU now probably want to reach an agreement via negotiations. This way they would try to prevent a long WTO process, both sides said.
References:
Generika für Drittstaaten: EU-Zoll blockiert. Pharmazeutische Zeitung PZ-Nachrichten. 07.08.2009.
EU blockiert Arzneimittel für Dritte Welt. Financial Times Deutschland. 2009 Aug 07.
Source: Pharmazeutische Zeitung PZ-Nachrichten; Financial Times Deutschland
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Reports
FTC reveals extent of PBM drug mark-ups and profits
Latin American patients face 4.7-year wait for innovative treatments
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
NPRA Malaysia trials new timelines for variation applications

Home/Policies & Legislation Posted 05/11/2024
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US

Home/Policies & Legislation Posted 18/09/2024
China’s NMPA expands global ties with the Netherlands and Indonesia

Home/Policies & Legislation Posted 04/09/2024
Japan's PMDA expands influence with new office in Thailand

Home/Policies & Legislation Posted 06/08/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment